Loading...
Please wait, while we are loading the content...
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
| Content Provider | Scilit |
|---|---|
| Author | Chen, Yi-Bin Shah, Nirav N. Renteria, Anne S. Cutler, Corey Jansson, Johan Akbari, Mona Chen, Chunlin Quadri, Syed Parfionovas, Andrejus Devine, Steven M. |
| Copyright Year | 2019 |
| Description | Key Points In adults undergoing allo-HSCT, vedolizumab IV 300 mg was well tolerated and had a low incidence of overall and lower-intestinal aGVHD. These phase 1b data support further evaluation of vedolizumab for the prevention of aGVHD in adults undergoing allo-HSCT. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963235/pdf |
| Ending Page | 4146 |
| Page Count | 11 |
| Starting Page | 4136 |
| DOI | 10.1182/bloodadvances.2019000893 |
| Journal | Blood advances |
| Issue Number | 23 |
| Volume Number | 3 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2019-12-10 |
| Access Restriction | Open |
| Subject Keyword | Hematology Research and Experimental Medicine Hematopoietic Graft Adults Transplantation Allogeneic Vedolizumab Undergoing Tolerated Journal: Blood advances (Vol- 136, Issue- 23) |
| Content Type | Text |
| Resource Type | Article |